Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.